



Embargo: November 7, 2007 at 8:30 AM (Brussels Time)

## NEW CLINICAL DATA SHOW SOLVAY'S FENOFIBRATE CUTS RISK OF MAIN CAUSES OF VISION LOSS IN PATIENTS WITH TYPE 2 DIABETES

*Fenofibrate offers opportunity to protect patients from most serious consequences of type 2 diabetes*

SOLVAY welcomes the publication of the results of a study showing that fenofibrate, its product line in dyslipidemia (control of cholesterol and triglycerides), significantly reduces the need for treatment of the main causes of vision loss in patients with type 2 diabetes. The study shows that fenofibrate decreases the need for laser therapy for diabetic eye disease by more than 30 percent. These important, new results were published online in the *Lancet* ([www.thelancet.com](http://www.thelancet.com)) yesterday by investigators from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Principal investigator of the study is Professor Anthony Keech of the University of Sydney (Australia).

In addition to reducing the need for laser therapy in the overall population, fenofibrate showed, in a substudy of approximately 1,000 patients with preexisting eye disease, a significant reduction in the progression of this disease.

Eye disease, including diabetic retinopathy and macular oedema, affects up to 50 million of the 200 million people with diabetes worldwide. After about 10 years of diabetes, a substantial proportion of patients will experience clinically significant changes in their vision.

Additional results from the main FIELD study show that fenofibrate significantly decreased the risk of non-traumatic amputations. Earlier data demonstrated that fenofibrate also significantly reduces microalbuminuria, a marker of the risk of progressive renal disease.

For detailed information, visit the FIELD website at [www.fieldstudy.info](http://www.fieldstudy.info).

**Solvay Pharmaceuticals** is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology, and men's and women's health. Its 2006 sales were EUR 2.6 billion and it employs approximately 10,000 people worldwide. For more information, visit [www.solvaypharmaceuticals.com](http://www.solvaypharmaceuticals.com).

**SOLVAY** is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs some 29,000 people in 50 countries. In 2006, its consolidated sales amounted to EUR 9.4 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at [www.solvay.com](http://www.solvay.com)

*For further information please contact:*

**MARTIAL TARDY**

*Corporate Press Officer*

SOLVAY S.A.

Phone: 32 2 509 72 30

E-mail: [martial.tardy@solvay.com](mailto:martial.tardy@solvay.com)

Internet: [www.solvaypress.com](http://www.solvaypress.com)

**PATRICK VERELST**

*Investor Relations*

SOLVAY S.A.

Phone: 32 2 509 72 43

E-mail: [patrick.verelst@solvay.com](mailto:patrick.verelst@solvay.com)

Internet: [www.solvay-investors.com](http://www.solvay-investors.com)

**Dr WERNER VAN DEN EYNDE**

*Pharmaceutical Communications*

SOLVAY PHARMACEUTICALS B.V.

Tel: 32 2 509 62 27

E-mail: [werner.vandeneynde@solvay.com](mailto:werner.vandeneynde@solvay.com)

Internet: [www.solvaypharmaceuticals.com](http://www.solvaypharmaceuticals.com)

Ce communiqué de presse est également disponible en français – Dit persbericht is ook in het Nederlands beschikbaar